New pill targets virus-driven cancer in patients with no other options
NCT ID NCT04925544
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 28 times
Summary
This study tests a new drug called VK 2019 in 13 people with Epstein-Barr virus (EBV) positive nasopharyngeal cancer or other EBV-related cancers that cannot be cured with standard treatments. The drug works by blocking a key viral protein (EBNA1) that helps the cancer grow. The main goal is to see if the drug shrinks tumors or slows the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Stanford University
Stanford, California, 94305, United States
Conditions
Explore the condition pages connected to this study.